NCT01217736已完成1 期
Direct Renin Inhibition and the Kidney
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- renal plasma flow
研究概览
简要总结
The objective of the study is to determine the magnitude of the effect of direct renin inhibition by VTP-27999 on renal plasma flow and kidney function.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult male or female, 18-75 years of age
- •Female subjects must be postmenopausal or surgically sterilized. Postmenopausal females must have had no regular menstrual bleeding for at least one (1) year prior to initial dosing. Menopause will be confirmed by plasma serum FSH level at screening between 23.0-116.3 mIU/ml. Female subjects who report surgical sterilization must have had the procedure at least six (6) months prior to initial dosing.
- •Male subjects, able to father a child, must be willing to use approved birth control methods for 2 weeks following completion of study.
排除标准
- •Subjects under 18 and subjects over 75 years
- •Diabetes Mellitus and/or kidney disease
- •Myocardial infarction, stroke, or cardiovascular revascularization/angioplasty within the last 6 months
- •Unstable angina pectoris or CAD requiring treatment with an excluded concomitant medication
- •History of/or symptoms consistent with congestive heart failure
- •Hypertension
- •History of left ventricular ejection fraction < 45%
- •Current smokers or nicotine patch
- •Pregnant or lactating females
- •Cancer or any life threatening illness with expected death within 2 years or by completion of the study
- •Serum creatinine >1.4 mg/dl
- •Serum potassium <3.5 or >5.2 mmol/L without medication
- •Serum albumin < 2.0 g/dL
- •Hemoglobin < 11.5 g/dL or Hematocrit < 34%
- •Any serum AST >/= 60 or ALT >/= 75 IU/L
- •Use of any prescription drugs which may affect the renin-angiotensin-aldosterone system or with known effect on renal hemodynamics are not allowed within 10 days prior to dosing or during the study
- •Use of CYP3A4 inhibitors (e.g. Diltiazem, Ketoconazole, Nifedipine, or Verapamil)
- •Use of any prescription medication is prohibited within 14 days (or, if known, for at least 5 half-lives, if longer) prior to dosing, unless approved by both the Investigator and the Sponsor
- •Use of any over-the-counter (OTC) medication, including herbal products, is prohibited within the 14 days prior to dosing, unless approved by both the Investigator and the Sponsor
- •Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing
- •A known hypersensitivity or contraindication to the study drugs (Aliskiren) or drugs similar to the study drugs or PAH, and inulin
- •Any surgical or medical condition which alters absorption, distribution, metabolism or excretion of drugs or which may jeopardize the patient subject during this study, including gastric bypass
- •History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by past medical history
- •Acute infections and/or significant illness within 3 weeks of planned enrollment into this study
- •Any medical condition in the investigator's opinion, which renders the subject unable to complete the study or which would produce significant risk to the subject
- •Administration of any other investigational drug within 30 days of planned dosing in the study
- •Poor intravenous (IV) access as determined by the study staff
研究组 & 干预措施
VTP-27999
Experimental
干预措施: VTP-27999 (Drug)
aliskiren
Active Comparator
干预措施: aliskiren (Drug)
placebo
Placebo Comparator
干预措施: placebo (Drug)
结局指标
主要结局
renal plasma flow
时间窗: pre-dose to 6 hours post-dose
as measured by PAH clearance
次要结局
- RAAS pathway biomarkers(pre-dose to 24 hours post-dose)
- VTP-27999 concentrations(pre-dose to 24 hours post-dose)
- glomerular filtration rate(pre-dose to 6 hours post-dose)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Effect of direct renin-inhibition aliskiren on renal haemodynamic and metabolic parameters in patients with prediabetes - AMARYLISEUCTR2008-008287-28-DEniversity Hospital Erlangen20
已完成
不适用
Therapeutic effects of direct renin inhibitor in end stage kidney disease patients with maintenance hemodialysisHypertension,End stage kidney diseaseJPRN-UMIN000003551Yamamoto general hospital40
已完成
不适用
The Effect of Renin Inhibition on Nerve Function in DiabetesDiabetesNCT00935064Christiana Care Health Services60
已完成
4 期
Shiga Microalbuminuria Reduction Trial-2Type 2 Diabetes MellitusHypertensionNCT01461499Shiga University237
已完成
不适用
The comparative study between direct renin inhibitor and angiotensin II receptor antagonist in hypertensive patients with chronic kidney diseasechronic kidney diseaseJPRN-UMIN000003817Division of Nephrology, Hypertension and Endocrinology, Itabashi Hospital, Nihon University School of Medicine40